
- /
- Supported exchanges
- / MX
- / SNYN.MX
Sanofi (SNYN MX) stock market data APIs
Sanofi Financial Data Overview
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, yellow fever, and rabies vaccines. In addition, the company has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab, as well as an strategic alliance with the Department of Health " Abu Dhabi for the development of global vaccines. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incor
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Sanofi data using free add-ons & libraries
Get Sanofi Fundamental Data
Sanofi Fundamental data includes:
- Net Revenue: 45 166 M
- EBITDA: 12 148 M
- Earnings Per Share: 54
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Sanofi News

Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock?
Shares of Kymera KYMR have surged 70.7% in the past three months compared with the industry’s gain of 9.7%. The stock has also outperformed the sector and the S&P 500 index during this timeframe. T...


Adult-onset Still Disease Market Research Report 2025-2035 | Personalized Medicine and Biomarker Discoveries Enhance Treatment Outcomes
Company Logo Adult-onset Still’s Disease (AOSD) is a rare, systemic inflammatory disorder characterized by high fevers, rashes, and arthritis, impacting adults with severe complications. The global...

Fabry Disease Treatment Analysis Report 2025 | Market to Reach $3.86 Billion by 2030, Rising Fabry Disease Prevalence and Demand for Targeted Therapies Drive Growth
Company Logo The global Fabry disease treatment market is projected to grow from USD 2.22 billion in 2024 to USD 3.86 billion by 2030. This expansion is driven by the rising prevalence of Fabry disea...

Press Release: Sanofi completes acquisition of Blueprint Medicines
Sanofi Winthrop Industrie Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Bluep...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.